Oppenheimer & Co’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
Other funds holding AUPH
Oppenheimer & Co's AUPH Position: Q3 2026 in Review
Oppenheimer & Co held its Aurinia Pharmaceuticals (AUPH) position steady in Q3 2026 at 12,520 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #1623.
Oppenheimer & Co first reported a position in AUPH in Q1 2021 and has held it in 23 quarters since. The position peaked at $457K in Q4 2021. 276 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.
- Oppenheimer & Co held 12,520 shares of Aurinia Pharmaceuticals worth $203K as of Q3 2026.
- Oppenheimer & Co left its Aurinia Pharmaceuticals share count unchanged in Q3 2026.
- Aurinia Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1623 holding.
- Oppenheimer & Co first reported a position in Aurinia Pharmaceuticals in Q1 2021 and has held it in 23 quarters since.
- Oppenheimer & Co's Aurinia Pharmaceuticals position peaked at $457K in Q4 2021.
- 276 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.
Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.